1. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy
   Simona Coco et al, 2017, IJMS CrossRef
2. Circulating Cell-Free Tumour DNA in the Management of Cancer
   Glenn Francis et al, 2015, IJMS CrossRef
3. Liquid biopsy - emergence of a new era in personalized cancer care
   Jessy Abraham et al, 2018, Appl Cancer Res CrossRef
4. Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer
   Ivana Bratić Hench et al, 2018, Front. Med. CrossRef
5. Circulating tumor DNA as prognostic markers for late stage NSCLC with bone metastasis
   Jiguang Jia et al, 2018, The International Journal of Biological Markers CrossRef
6. Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis
   Sarah Cargnin et al, 2017, Journal of Thoracic Oncology CrossRef
7. Diagnostic and prognostic impact of cell-free DNA in human cancers: systematic review
   Klara Cervena et al, 2019, Mutation Research/Reviews in Mutation Research CrossRef
8. Biomarkers of Lung Cancer: Liquid Biopsy Comes of Age
   Akihiko Miyanaga et al, 2019 CrossRef
9. Development in the diagnostic lung cancer pathway: implication for treatment
   Cristina Migali et al, 2014, Lung Cancer Management CrossRef
10. Saliva‐derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non‐small cell lung cancer
    Shanshan Ding et al, 2019, Thorac Cancer CrossRef
11. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients
    L. Sorber et al, 2017, Lung Cancer CrossRef
12. Lung Cancer Staging and Prognosis.
    Gavitt A Woodard et al, 2016, Cancer Treat Res CrossRef
13. The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis
    Rongyuan Zhuang et al, 2017, PLoS ONE CrossRef
14. Prognostic value of pre-treatment red blood cell distribution width in lung cancer: a meta-analysis
    Yan Wang et al, 2020, Biomarkers CrossRef
15. Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma
    Álvaro Taus et al, 2020, Archivos de Bronconeumología CrossRef
16. Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
    Pieter A. Boonstra et al, 2020, Cancer Metastasis Rev CrossRef
17. The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review
    Frederik van Delft et al, 2020, Cancers CrossRef
18. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC
    Yang Yang et al, 2017, Oncotarget CrossRef
19. Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis
    Hongchang Shen et al, 2017, Oncotarget CrossRef
20. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer
    Bo Ai et al, 2016, Oncotarget CrossRef
21. Application of Circulating Cell‐free DNA for Personalized Cancer Therapy
    Indranil Chattopadhyay, 2020 CrossRef
22. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy
    Sissel Gyrid Freim Wahl et al, 2021, J Pathol Clin Res CrossRef
23. Develop Micro/Nano Technologies for Cancer Diagnosis
    Si-Yang Zheng, 2021 CrossRef
24. Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma
    Álvaro Taus et al, 2021, Archivos de Bronconeumología (English Edition) CrossRef
25. The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC
    Xiaolong Zhao et al, 2021, Front. Oncol. CrossRef
26. Correlation of transrenal DNA with non-small-cell lung cancer in noninvasive disease monitoring
    Ziyang Zhu et al, 2021, Biomarkers in Medicine CrossRef
27. Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA
    Stephanie J. Yaung et al, 2022, Cancers CrossRef
28. Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy
    Weiying Kong et al, 2023 CrossRef
29. A robust six-gene prognostic signature based on two prognostic subtypes constructed by chromatin regulators is correlated with immunological features and therapeutic response in lung adenocarcinoma
    Qiang Chen et al, 2023, Aging CrossRef
30. An Investigation into Cell-Free DNA in Different Common Cancers
    Samira Nafar et al, 2023, Mol Biotechnol CrossRef
31. Diagnostics and Therapy for Malignant Tumors
    Chung-Che Tsai et al, 2024, Biomedicines CrossRef